VIRI Virios Therapeutics Inc
4,228
$0.4284
$0.0184
(4.49%)
| Watchers | 4,228 |
| 52-Wk Low | $0.279 |
| 52-Wk High | $2.42 |
| Market Cap | $7.9M |
| Volume | 37,937.00 |
| 52-Wk High | $2.42 |
| 52-Wk Low | $0.279 |
Virios Therapeutics, Inc. (NASDAQ:VIRI) Sees Significant Growth in Short InterestZolmax • about 1 month ago
Virios Therapeutics, Inc. (NASDAQ:VIRI - Get Free Report) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 170,200 shares, a growth...
Share to Feed
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses...
Gagnants
Le titre IMAC Hldgs (NASDAQ:BACK) a augment vendredi de 96,12% 2,53 dollars lors de la session ordinaire.
L'action Ontrak (NASDAQ:OTRK) a grimp de 34,65% 0,35 dollars.
Le titre Virios...
Virios Therapeutics, Inc. (NASDAQ:VIRI Get Free Report) was the target of a significant drop in short interest during the month of February. As of February 29th, there was short interest...
ATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the Company ), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
ATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the Company ), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
- Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 -- Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 - ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios...
Virios Therapeutics, Inc. (NASDAQ:VIRI Get Free Report)s stock price traded down 8.3% on Wednesday . The company traded as low as $0.53 and last traded at $0.53. 257,149 shares were...
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the Company ), a development-stage biotechnology company focused on developing novel antiviral therapies to...